Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Antibodies to COVID-19 fall by half in less than 90 days, and antibody levels peak lower and fall faster in younger adults, an ongoing study of staff at Oxford University Hospitals NHS Foundation Trust has revealed.

Swab testing in the OUH laboratories © Jon Lewis, Oxford Hospitals Charity

The findings, published on the pre-print server medRxiv, also showed that antibodies to the virus last longer in people who have had symptoms, and fade quicker in those who were asymptomatic.

The paper – ‘The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers’ – presents six months of data from a longitudinal seroprevalence study of 3,217 OUH healthcare workers who have attended more than once for antibody testing.

They were among some 10,000 staff across OUH’s four hospitals who have been tested both for presence of the virus responsible for COVID-19 and antibodies to the virus, to give an accurate picture of who among the OUH workforce had had coronavirus infection. The study is a major collaboration between OUH and the University of Oxford, with support from the NIHR Oxford Biomedical Research Centre.

By measuring antibody responses in the same healthcare workers for up to six months, the researchers could follow what happens to antibody levels over time and how this varied between different people.

The full story is available on the NIHR Oxford Biomedical Research Centre website

It is also featured on the Nuffield Department of Population Health website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.